Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Chronic Myelogenous Leukemia: New Targeted Therapies Take Aim at Gleevec

Published by: Decision Resources

Published: Aug. 27, 2009 - 22 Pages


Table of Contents


Executive Summary
Strategic Considerations

Stakeholder Implications

Introduction

Disease Overview

Etiology and Pathophysiology

BCR-ABL-Positive Patients

BCR-ABL-Negative Patients

Diagnosis and Classification

Patient Population, Symptoms, and Disease Progression

Current Therapies

Drug Therapies

Novartis’s Gleevec

Novartis’s Tasigna

Bristol-Myers Squibb’s Sprycel

Interferon-Alpha

Generic Chemotherapeutic Agents

Progenitor Stem Cell Transplantation

Myeloablative Regimens

Allogenic Progenitor Stem Cell Transplantation

Autologous Progenitor Stem Cell Transplantation

Emerging Therapies

Wyeth’s Bosutinib (SKI-606)

Novartis’s Panobinostat (LBH-589)

ChemGenex Pharmaceuticals’ Omacetaxine Mepesuccinate

2008 Statistics and Market Outlook

Tables

1. Laboratory Features Characteristic of Chronic Myelogenous Leukemia

2. Poor Prognostic Factors for Chronic-Phase Chronic Myelogenous Leukemia

3. Commonly Used Current Therapies in the Treatment of Chronic Myelogenous Leukemia

4. Emerging Therapies for Chronic Myelogenous Leukemia

5. 2008 Worldwide Chronic Myelogenous Leukemia Market

Figures

1. The Philadelphia-Chromosome

2. Prevalent, Diagnosed Cases of Chronic Myelogenous Leukemia in the Major Pharmaceutical Markets, 2008 and 2013

Abstract

Introduction

Chronic myelogenous leukemia (CML) is a rare blood cancer; nonetheless, CML treatments garner substantial revenues. Despite recent advances in the treatment of this disease (most notably, targeted therapeutics such as Novartis's Gleevec/Glivec [imatinib]), significant unmet needs remain because certain segments of the CML patient population are intolerant of or become resistant to existing therapies. Emerging therapies that focus on the unmet needs of current therapeutics have a good chance of replicating Gleevec's success.

Questions Answered in This Report
  • Properly diagnosing CML is an integral part of choosing an effective treatment. How is CML diagnosed? What role does genetic testing play in developing and deploying drugs for CML? What are the symptoms of CML?
  • Treatment options for CML are more targeted today than in recent history. How was CML previously treated? Why have targeted therapies proved to be better CML treatment options?
  • Despite treatment advances, opportunities remain for emerging CML agents. What are these opportunities? Are the opportunities potentially lucrative enough to motivate drug developers?
Scope
  • Disease overview: disease causes and indicators, physical and genetic symptoms, diagnosis, classification, epidemiology, and disease progression.
  • Current CML therapies: chemotherapy, interferon-alpha, targeted therapies, stem cell therapy.
  • Emerging CML therapies: targeted therapies, therapies focused on particular disease mutations.
  • Market outlook: 2008 CML market sales, opportunities for current and emerging CML therapies.
Please note, the PDF e-mail from publisher version of this report is for a global site license.

Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2012
2/15/2012 - 31